Sign In
Buy HKMPY
$44.37
+0 (+0%)
At Close: Jul 31, 2026
Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US
07:00am, Tuesday, 03'rd Oct 2023
Important milestone in combatting the opioid overdose epidemic LONDON , Oct. 3, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the
SAN DIEGO , Aug. 10, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox�
Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases
12:45pm, Wednesday, 26'th Jul 2023
LONDON , July 26, 2023 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures , has invested in Octave Bio
Selling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 Months
05:25am, Saturday, 06'th May 2023
Hikma Pharmaceuticals is a FTSE 250 generic drug manufacturer that was founded in the Middle East in 1978. The company has many attractive features, including a long track record of progressive divide
Hikma Pharmaceuticals PLC (HKMPF) Q4 2022 Earnings Call Transcript
01:13pm, Sunday, 26'th Feb 2023
Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2022 Earnings Conference Call February 23, 2023 6:00 AM ET Company Participants Susan Ringdal - EVP, Strategic Planning and Global Affairs Said Darwazah - Ch
Hikma Pharmaceuticals higher as Citi analysts revise target price
04:32am, Thursday, 05'th Jan 2023
Analysts at Citi have revised their net present value (NPV)-based price target for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to £19.20 with a £28-£11 bull-bear valuation range for the stock.
Hikma Pharmaceuticals launches generic version of narcolepsy treatment Xyrem in US
04:11am, Tuesday, 03'rd Jan 2023
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) said it has launched an authorised generic version of Jazz Pharmaceuticals' Xyrem (sodium oxybate) oral solution CIII. Sodium Oxybate oral solution, 0
Hikma Pharmaceuticals Plc (HKMPF) 2022 Interim Results - Earnings Call Transcript
04:34pm, Friday, 05'th Aug 2022
Hikma Pharmaceuticals Plc. (OTCPK:HKMPF) 2022 Interim Results August 4, 2022 5:30 AM ET Company Participants Said Darwazah - Executive Chairman & CEO Khalid Nabilsi - CFO Conference Call Participants
Hikma Pharmaceuticals loses CEO
03:48am, Tuesday, 24'th May 2022
The chief executive of Hikma Pharmaceuticals PLC (AIM:HIK, OTC:HKMPF), Siggi Olafsson, has stepped down from the role, with a permanent replacement yet to be found. The British injectable medicine bus
Hikma Pharmaceuticals PLC (HKMPF) CEO Sigurdur Olafsson on Q4 2021 Results - Earnings Call Transcript
11:34pm, Thursday, 24'th Feb 2022
Hikma Pharmaceuticals PLC (HKMPF) CEO Sigurdur Olafsson on Q4 2021 Results - Earnings Call Transcript
Hikma Pharmaceuticals sales grow 9%, announces US$300mln share buyback
05:51am, Thursday, 24'th Feb 2022
Hikma Pharmaceuticals PLC (AIM:HIK, OTC:HKMPF) reported “solid growth” for 2021, with sales rising 9% on the back of a good performance in all its three businesses. The multinational pharmaceuti
